echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Oral complement C5a receptor inhibitor approved in Japan

    Oral complement C5a receptor inhibitor approved in Japan

    • Last Update: 2021-10-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    ▎ WuXi AppTec content team editor On September 27, 2021, ChemoCentryx, Vifor Pharma, and Kissei Pharmaceutical jointly announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan has approved Tavneos (avacopan) to be marketed in Japan


    Avacopan is an orally administered selective complement C5a receptor (C5aR) inhibitor for the treatment of two major anti-neutrophil cytoplasmic autoantibodies (ANCA)-related vasculitis: Microscopic polyangiitis (MPA) ) And granuloma with polyangiitis (GPA)

    ANCA-associated vasculitis is a rare and serious autoimmune nephropathy with high unmet medical needs

    The press release pointed out that this is the first time this C5aR inhibitor has been approved globally

    It is currently undergoing review by the US FDA

    ANCA-associated vasculitis is a systemic disease in which excessive activation of the C5a complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels, which can cause organ damage and failure

    At present, the treatment of ANCA-related vasculitis includes non-specific immunosuppressants (cyclophosphamide or rituximab), combined with daily glucocorticoid long-term administration, which may lead to significant clinical risks, including death due to infection

    Avacopan precisely blocks C5aR located on inflammatory cells such as neutrophils, prevents these cells from being activated by C5a, and reduces inflammatory damage

    Image source: ChemoCentryx official website The approval is supported by the positive results of a pivotal Phase 3 trial

    Data from 331 patients with polyangiitis and granuloma with polyangiitis showed that according to the Birmingham Vasculitis Activity Score (BVAS), the remission rate of the avacopan group was better than standard treatment at the 52nd week of treatment

    ▲At the 52nd week of treatment, the remission rate of the avacopan group was better than that of the standard treatment (picture source: reference [3]).
    Specifically, at the 52nd week of treatment, 65.
    7% of the patients in the avacopan group observed sustained remission.
    The drug group was 54.
    9% (non-inferiority P<0.
    001; superiority P=0.


    In terms of safety, 37.
    3% of patients treated with avacopan and 39.
    0% of patients treated with control drugs had serious adverse events (excluding worsening of vasculitis)


    ChemoCentryx is also developing avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS) and lupus nephritis (LN)

    The FDA has granted avacopan an orphan drug designation for the treatment of ANCA-related vasculitis and C3 glomerulopathy

    Thomas J.
    Schall, President and CEO of ChemoCentryx, said: “This marks the first time that a new drug discovered and developed by ChemoCentryx has been approved by regulatory agencies


    We would like to thank Kissei and the Japanese Ministry of Health, Labour and Welfare for their time and great efforts to make This important milestone is made possible and is expected to bring relief to patients with significant unmet needs

    "Reference: [1] VFMCRP announces approval for Tavneos® (avacopan) for the treatment of ANCA-associated vasculitis in Japan.
    Retrieved September 27, 2021, from https:// en/[2] ChemoCentryx Announces Approval in Japan of Tavneos™ (Avacopan) for the Treatment of ANCA-Associated Vasculitis.
    Retrieved September 27, 2021, from https:// 27/2303617/19219/en/ChemoCentryx-Announces-Approval-in-Japan-of-Tavneos-Avacopan-for-the-Treatment-of-ANCA-Associated-Vasculitis.
    html[3] Avacopan for the Treatment of ANCA-Associated Vasculitis.
    New England Journal of Medicine, 384(21), e81.
    1056/nejmc2104672 Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress


    This article is only for For the purpose of information exchange, the opinions in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views
    in the
    article .
    This article is not a treatment plan recommendation.


    If you need guidance on the treatment plan, please go to a regular hospital for treatment

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.